HealthDay News — Two cases of a new strain of gonorrhea reported in Massachusetts were at least partly resistant to several antibiotics, state officials announced Thursday.
“The discovery of this strain of gonorrhea is a serious public health concern which DPH [Department of Health], the CDC, and other health departments have been vigilant about detecting,” Margret Cooke, head of the Massachusetts Department of Public Health, said in a statement. “We urge all sexually active people to be regularly tested for sexually transmitted infections and to consider reducing the number of their sexual partners and increasing their use of condoms when having sex.”
The patients in the two Massachusetts cases did improve after getting injections of the primary drug currently recommended for the sexually transmitted disease, ceftriaxone. Massachusetts health officials are now working with the U.S. Centers for Disease Control and Prevention to test other samples from other gonorrhea cases in the state. The state is also tracing contacts to see if the strain has spread further.
The two cases do not have a direct connection to each other. One case was found in a patient who had symptoms of urethritis. Of the two cases, one had no recent travel history, so the strain may be spreading within the state, CBS News reported.
Agency officials have long been concerned about drug resistance with this bacteria, calling gonorrhea one of the three most urgent threats back in 2013. “This case is a reminder that antimicrobial-resistant gonorrhea remains an urgent public health threat nationally and internationally; all providers in all clinical settings need to remain vigilant,” Laura Hinkle Bachmann, M.D., chief medical officer of the CDC Division of STD Prevention, said Thursday in a letter to providers, CBS News reported.
When the CDC tested drugs against the strain found in Massachusetts, only one had no signs of reduced effectiveness. That was gentamicin, which is already considered less effective against gonorrhea. Another potentially promising drug is being tested in clinical trials, but zoliflodacin has not yet been approved by the U.S. Food and Drug Administration for gonorrhea, CBS News reported.